Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study.

@article{Fried2013OncedailyS,
  title={Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-na{\"i}ve genotype 1 hepatitis C: the randomized PILLAR study.},
  author={Michael W. Fried and Mar{\'i}a Asunci{\'o}n But{\'i} and Gregory J Dore and R Flisiak and P Ferenci and Ira Jacobson and Patrick Marcellin and Michael M Manns and Igor A. Nikitin and Fred P Poordad and Morris Sherman and Stefan Zeuzem and Jane Anne Scott and Leen Gilles and Oliver Lenz and Monika Peeters and Vanitha J. Sekar and Goedele de Smedt and Maria Beumont-Mauviel},
  journal={Hepatology},
  year={2013},
  volume={58 6},
  pages={1918-29}
}
UNLABELLED The phase IIb, double-blind, placebo-controlled PILLAR trial investigated the efficacy and safety of two different simeprevir (SMV) doses administered once-daily (QD) with pegylated interferon (Peg-IFN)-α-2a and ribavirin (RBV) in treatment-naïve patients with HCV genotype 1 infection. Patients were randomized to one of five treatments: SMV (75 or 150 mg QD) for 12 or 24 weeks or placebo, plus Peg-IFN and RBV. Patients in the SMV arms stopped all treatment at week 24 if response… CONTINUE READING